Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D‑phenylalanyl‑N‑{4‑[amino(iminio)methyl]benzyl}‑L‑prolinamide is a synthetic dipeptide small molecule with the chemical formula C22H28N5O2 and a molecular weight of approximately 394.5 g/mol. It is classified as an experimental compound and has not been approved for clinical use in any jurisdiction. There are no known indications, associated conditions, or completed clinical trials for this molecule. Its mechanism of action, pharmacological activity, and therapeutic potential have not been described in publicly available sources[3][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide.